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We evaluated an enzyme-linked immunospot assay for
interferon-γ (T SPOT-TB) for rapid diagnosis of active
tuberculosis (TB) in a disease-endemic area. From January
to June 2005, patients whose clinical symptoms and radi-
ographic findings were compatible with TB were recruited,
and a blood sample was obtained for T SPOT-TB assay
within 7 days of microbiologic studies. Sixty-five patients
were studied, including 39 (60%) with active TB. Thirty-five
(53.8%) patients had underlying medical conditions. Thirty-
seven patients had positive cultures for Mycobacterium
tuberculosis, and 11 patients had positive cultures for non-
tuberculous mycobacteria. The sensitivity, specificity, posi-
tive predictive value, and negative predictive value of the T
SPOT-TB assay were 87.2%, 88.5%, 91.9%, and 82.1%,
respectively. The accuracy of this test in diagnosing active
TB is >80%, even in an area with a high incidence of non-
tuberculous mycobacterial disease.
T
uberculosis (TB) is one of the most important infec-
tious disease in the world. In 2003, the incidence and
death rates for TB in Taiwan were 62.38 and 5.80 per
100,000, respectively (1). Successful control of TB
depends on prompt detection of patients with
Mycobacterium tuberculosis infection. The conventional
methods for laboratory diagnosis of TB, including acid-
fast staining and culture, are either insensitive (2,3) or
time-consuming (4). Although new diagnostic methods
that use nucleic acid amplification and detection may pro-
vide quick and specific results for identifying the M. tuber-
culosis complex (5,6), their sensitivities are considerably
less than those of culture (6).
Recent studies demonstrated that an enzyme-linked
immunospot (ELISPOT) assay for interferon-γ (IFN-γ)
produced by activated T cells after exposure to antigens of
M. tuberculosis, early secretory antigenic target 6 (ESAT-
6), and culture filtrate protein 10 (CFP-10) is a specific
method for identifying M.  tuberculosis infection (7–9).
However, its performance in rapid diagnosis of active TB
in disease-endemic areas is still unknown. We evaluated
the ELISPOT (T SPOT-TB) assay in clinically suspected
cases of TB.
Methods
Patients
This study was conducted from January to June 2005
in northern Taiwan at a tertiary care referral center with
2,000 beds; the study was approved by the ethics commit-
tee of the hospital. Patients with fever or respiratory symp-
toms (cough, dyspnea, or hemoptysis) for >2 weeks and
compatible radiographic findings were considered to have
clinically suspected cases of TB. The compatible findings
included fibroexudative or fibrotic lesions over upper lung,
pulmonary nodules with or without cavitation, multiple
patches of alveolar infiltrates, miliary shadowing, and
pleural effusion with lymphocytotic and exudative charac-
teristics. Patients were invited to provide informed consent
and were interviewed and examined. A blood sample was
obtained for ELISPOT within 7 days of microbiologic
studies (including acid-fast smears [AFS] and mycobacte-
rial culture). Twelve healthcare workers (HCWs) in the
hospital were included as a healthy control group.
Laboratory Procedures
AFS for respiratory samples and mycobacterial cul-
ture were performed as previously described (5). If the pri-
mary care physician deemed it necessary, samples were
screened for infection with HIV type 1 or type 2 viruses by
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Chinausing competitive ELISAs (Wellcome Laboratories,
Beckenham, UK), and infection was confirmed by Western
blotting (Diagnostics Pasteur, Marnes-la-Coquette,
France).
ELISPOT Assay
Five milliliters of blood was obtained from each
patient and processed within 2 hours. ELISPOT was per-
formed by using a commercial kit (T SPOT-TB; Oxford
Immunotec Ltd, Oxford, UK) as previously described (10).
Briefly, peripheral blood mononuclear cells were separat-
ed by using Ficoll-Paque centrifugation. Cells were
washed, resuspended, and counted. Ninety-six–well
polyvinylidene fluoride–backed plates (MAIPS4510;
Millipore, Billerica, MA, USA) were coated with 15
µg/mL of monoclonal antibody 1-D1K against IFN-γ
(Mabtech, Nacka Strand, Sweden). Cells (250,000/well)
were added to duplicate wells containing antigen (ESAT-6
or CFP-10) or mitogen. No antigen was added to the back-
ground control wells. After incubation for 18 h, plates were
washed, 100 µL (1  µg/mL) of biotinylated monoclonal
antibody 7-B6-1-biotin against IFN-γ (Mabtech) was
added, and plates were incubated for 2 h. Plates were then
washed, streptavidin-alkaline phosphatase toxoid
(Mabtech) was added and incubated for 1.5 h; plates were
washed again and 100 µL of chromogenic alkaline phos-
phatase substrate (Bio-Rad Laboratories, Hercules, CA,
USA) was added. After 10–15 min, the plates were washed
and spots were enumerated with a stereomicroscope inde-
pendently by 2 observers. Mean values determined by the
2 observers and both duplicate wells were used in all cal-
culations. The number of spots in the background control
wells was subtracted from the number in the test wells, and
a response was considered positive if the number of spots
per test well was >10 and at least twice the value found in
the background control wells.
Clinical Evaluation of Patients
All medical records including history, symptoms,
signs, radiologic, pathologic, and microbiologic results,
and follow-up observations were carefully reviewed to
obtain data for generating a clinical diagnosis. On the basis
of clinical findings, 2 categories of patients were consid-
ered to have active TB: those whose clinical specimens
were culture-positive for M. tuberculosis and those whose
biopsy specimens had caseating granulomas that showed
marked improvement after treatment.
Results
Patient characteristics are summarized in Table 1. All
patients were previously vaccinated with bacillus
Calmette-Guérin (BCG). Laboratory tests for HIV infec-
tion were performed for 42 patients and results were posi-
tive for 3 patients. Of 23 patients with an unknown HIV
status, all had an initial lymphocyte count >1 × 109/L and
did not have AIDS-defined illness (11). Thirty-nine (60%)
had active TB; 37 had culture-confirmed TB and 2 had
histopathology-proved TB with marked improvement of
their clinical conditions after treatment. Thirty-one
patients had pulmonary TB, 3 had TB pleurisy (M. tuber-
culosis was isolated from pleural effusion), and 2 had con-
comitant pulmonary TB and TB pleurisy. The remaining 3
patients had pulmonary and extrapulmonary TB. Of the 26
non-TB patients, all were culture negative for M. tubercu-
losis for multiple specimens (mean 8.3, range 3–20).
Eight (12.3%) fulfilled the diagnostic criteria for non-
tuberculosis mycobacterial (NTM) disease (12). Of these 8
patients, 2 infected with M. avium-intracellulare complex
responded to treatment with clarithromycin, ethambutol,
and rifampin; 1 infected with M. kansasii responded to
treatment with isoniazid, rifampin, and ethambutol; and 3
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clarithromycin. Clinical conditions and radiographic
abnormalities improved in 9 patients after treatment with
antimicrobial drugs and in 2 patients after treatment with
antifungal drugs. Three other patients provided biopsy
specimens, which showed malignancy in 2 patients and a
benign tumor in 1 patient. Another patient died of
Staphylococcus aureus pneumonia and bacteremia. Three
other patients showed no clinical and radiographic
improvement after empiric treatment for 2 weeks.
Specimens from 2 these patients were tested by a nucleic
acid amplification assay (BD ProbeTec ET DTB system;
Becton Dickinson Instrument Systems, Sparks, MD, USA)
and showed negative results. Nine of 12 patients with dia-
betes and the 3 patients infected with HIV had active TB.
In the 48 patients with mycobacteria isolated from respira-
tory specimens, the average interval between the date
when microbiologic studies were performed and the date
when the result of mycobacterial culture was available was
49.9 days (range 14–77 days). However, the average inter-
val for the ELISPOT assay for these patients was 4.5
days (range 1–8 days) after microbiologic studies were
performed.
Table 2 shows the correlation between ELISPOT
results and the final diagnosis for the 65 patients. Of the 22
patients with AFS-positive TB, 19 (86.4%) were ELISPOT
positive. Three showed false-negative results in the
ELISPOT, including a 41-year-old HIV-positive man, a
47-year-old HIV-negative man with diabetes mellitus, and
a 78-year-old woman with diabetes mellitus and Sjogren
syndrome. Of the 11 non-TB patients with positive AFS,
mycobacterial culture showed NTM disease in 8 patients.
Three showed false-positive results in the ELISPOT,
including a 74-year-old man with diabetes who was culture
positive for M. chelonae, a 50-year-old previously healthy
man who was culture positive for M. marinum, and a 21-
year-old previously healthy woman who was culture posi-
tive for M.  avium-intracellulare complex. The positive
predictive value (PPV) of ELISPOT for AFS-positive
patients was 86.4% (Table 2).
Of the 17 patients with AFS-negative TB, 2 (11.8%)
showed negative results in the ELISPOT (Table 2). Both
were previously healthy and had culture-positive TB
pleurisy with pleural effusions with lymphocytotic and
exudative characteristics. Chest radiographs for these 2
patients showed pleural effusion without parenchymal
lesions. Their sputum cultures were negative for M. tuber-
culosis. HIV status was tested in only 1 patient. For the 15
non-TB patients with negative AFS, all showed negative
results in the ELISPOT, i.e., the specificity and PPV of the
ELISPOT were 100% (Table 2).
Among the 28 ELISPOT-negative patients, 3, includ-
ing 1 with culture-confirmed TB, were retested 2, 4, and 5
weeks later, respectively. All were again ELISPOT nega-
tive. Among the 12 HCWs, all were ELISPOT negative
except 1 who previously had culture-confirmed TB and
had been treated for 10 months.
Discussion
Delayed diagnosis and treatment can increase the risk
for dissemination of M. tuberculosis and decrease survival
for some subgroups of TB patients (13–15). Thus, new
technologic developments, which facilitate rapid diagno-
sis, are needed for successful control of this disease.
Besides the development of nucleic acid amplification
assays for rapid detection of M.  tuberculosis complex,
attempts have been made to exploit the T-cell response  for
rapid diagnosis of M. tuberculosis infection (16,17). The
major problem with tuberculin skin testing (TST) is cross-
reactivity with antigens in other mycobacteria, such as the
M. bovis BCG vaccine strain and environmental mycobac-
terial species. This cross-reactivity leads to false-positive
results and decreased PPV, especially in BCG-vaccinated
persons and in areas of high incidence of NTM disease,
such as Taiwan. In Taiwan in 2001, 2.74% of preschool
children were TST positive, whereas active TB developed
in only 2.29/100,000 children 5–9 years of age (1). Use of
ESAT-6 and CFP-10, two antigens encoded in the region of
difference 1, which distinguishes M.  tuberculosis from
other mycobacteria, has increased the specificity and PPV
of IFN-γ ELISPOT assays (10,18–22). Our study showed
that the sensitivity, specificity, PPV, and negative predic-
tive values (NPV) of the ELISPOTassay were >80% in the
diagnosis of active TB in clinically suspected patients.
Results were also available ≈45 days earlier than those
obtained with mycobacterial culture.
The genes coding for ESAT-6 and CFP-10 are absent
from most environmental mycobacteria, except for M.
kansasii, M. marinum, M. szulgai, M. flavescens, and M.
gastrii (23–25). Whether ESAT-6 or CFP-10 is present in
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not yet been determined. Although PPV is associated with
pretest probability of active TB in a cohort, our results
showed that the ELISPOT can accurately discriminate TB
from NTM disease and other respiratory diseases. All 3
patients with false-positive ELISPOT results had NTM
disease. The 3 AFS-positive TB patients with false-nega-
tive ELISPOT results had other diseases (2 had diabetes
mellitus and 1 had AIDS), which could weaken the T-cell
response (26,27). However, neither of the 2 AFS-negative
ELISPOT false-negative TB patients had another disease.
Because HIV status was not routinely tested, the possibili-
ty of asymptomatic HIV infection that potentially influ-
enced the ELISPOT results cannot be excluded.
Consistent with previous reports (sensitivity
80.7%–94.4%) (20,28–30), assays detecting secretion of
IFN-γ caused by stimulation with ESAT-6 or CFP-10 for
diagnosis of TB have a sensitivity >80%. However, speci-
ficity (45.5%–69.2%), PPV (65.4%–85.4%), and NPV
(53.6%– 90.0%) were highly variable, which was probably
due to different criteria for patient selection and diagnosis
of active TB. In a study conducted in Japan (20), only
patients with culture-confirmed infection were considered
to have active TB. Thus, culture-negative TB patients
would be classified into a non-TB group, but some showed
positive test results, which resulted in decreased specifici-
ty and PPV. In the study conducted in Denmark (28), sev-
eral risk factors predisposing persons to recent M.
tuberculosis infection were observed in the 10 patients
with false-positive results, including a history of recent
exposure, immigration from a highly disease-endemic
area, intravenous drug use, and HIV positivity. In the study
conducted in Brazil (30), controls were medical students,
who were at high risk for nosocomial exposure; 50% of
them were ELISPOT positive, which resulted in low speci-
ficity and PPV.
Many of our patients without active TB were
ELISPOT negative. In a study in Taiwan in 2001, 2.74% of
preschool children were TST positive, and the annual esti-
mated infection rate was 0.43% (1). Therefore, it is unlike-
ly that all of our ELISPOT-negative patients had never
been infected with M.  tuberculosis. Furthermore, the
results with samples from HCWs decrease the possibility
that acute illness caused a false-negative result. Previous
studies with sequential testing showed that responses of
ESAT-6– or CFP-10–specific T cells decay progressively
with treatment for TB (9,22,31–34). Our ELISPOT-nega-
tive patients may not have been recently infected with M.
tuberculosis; thus, levels of their circulating ESAT-6– or
CFP-10–specific effector T cells, rather than memory T
cells, decreased and failed to yield a positive ELISPOT
result (35,36). Further long-term follow-up study of
ELISPOT-positive TB patients is needed to better under-
stand the dynamic changes in ESAT-6– or CFP-10–specif-
ic effector T cells.
Patients with AFS-negative TB should be further
investigated because this type of TB is usually diagnosed
late and has been reported to be responsible for ≈17% of
TB transmission (37,38). Our study showed that all AFS-
negative ELISPOT-positive patients had true cases of TB,
i.e., PPV = 100%. Only 2 patients with TB pleurisy and
negative sputum culture for M. tuberculosis showed false-
negative ELISPOT results. The cause of this finding is not
known because the current hypothesis for the pathogenesis
of TB pleurisy is that the caseous material from a subpleur-
al focus ruptures into the pleural space 6–12 weeks after a
primary infection. This material then interacts with previ-
ously sensitized T cells, which results in a delayed hyper-
sensitivity reaction and accumulation of fluid (39,40). The
2 patients with false-negative ELISPOT results might have
been at a early stage of primary TB, and their sensitized T
cells had not yet returned to the systemic circulation before
sampling was conducted. Further investigation is needed
to assess the performance of the ELISPOT assay in
patients suspected of having TB with negative AFS results.
The resurgence of TB has prompted the need for sen-
sitive, accurate, and fast methods for laboratory detection
of  M.  tuberculosis infection. Although previous studies
demonstrated that the ELISPOT assay for INF-γ is a pow-
erful tool for detecting latent M. tuberculosis infection, our
results showed that in patients who were previously vacci-
nated with BCG, the diagnostic value of this test in detect-
ing active TB approached 90% in sensitivity, specificity,
PPV, and NPV, even in an area with a high incidence of
NTM disease.
Dr Wang is an attending physician at the National Taiwan
University Hospital and a student at the Graduate Institute of
Clinical Medicine, National Taiwan University. His primary
research interest is pulmonary infectious disease, especially TB.
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